EKF Diagnostics Holdings plc (AIM:EKF)

Market Cap	111.41M +1.9%
Revenue (ttm)	50.22M -1.4%
Net Income	6.12M +28.1%
EPS	0.01 +28.3%
Shares Out	431.82M
PE Ratio	19.10
Forward PE	17.67
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87,913
Average Volume	128,348
Open	25.90
Previous Close	25.80
Day's Range	25.08 - 25.90
52-Week Range	18.40 - 32.00
Beta	0.54
RSI	50.64
Earnings Date	Mar 23, 2026

About EKF Diagnostics Holdings

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Cl...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1990
• Employees: 297
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: EKF

Financial Performance

In 2024, EKF Diagnostics Holdings's revenue was 50.19 million, a decrease of -4.59% compared to the previous year's 52.61 million. Earnings were 6.24 million, an increase of 165.39%.